Illumina(US:ILMN) 仪器信息网·2025-08-20 03:55Core Viewpoint - Illumina reported a second-quarter revenue of $1.06 billion, a year-on-year decline of 3%, while adjusting its full-year revenue forecast to $4.23 billion to $4.31 billion, indicating a strategic shift towards multi-omics [2][4][6]. Financial Performance - The second-quarter revenue was $1.06 billion, down 2.8% year-on-year but up 1.7% quarter-on-quarter [4]. - Gross margin was 65.6%, down from 68.0% in the same period last year [4]. - Operating cash flow was $234 million, and free cash flow was $204 million [4]. - The company repurchased 4.5 million shares at an average price of approximately $85, with about $800 million remaining in the authorization [4]. Regional Revenue Breakdown - Revenue from Greater China was $63 million, a year-on-year decline of 16% [4]. - Instrument sales in Greater China fell by 40%, while reagent services decreased by 5% [4]. - European revenue was $310 million, a year-on-year increase of 7.3% [4]. - Americas revenue was $586 million, down 5.5% year-on-year [4]. - AMEA revenue was $100 million, down 7.4% year-on-year [4]. Product Sales and Strategic Initiatives - Sequencing instrument sales were approximately $96 million, with NovaSeq X shipments declining to around 50 units [5]. - Sequencing consumables revenue was $740 million, flat year-on-year but up 6% quarter-on-quarter [5]. - Since the new strategy was announced in August 2025, Illumina has been transitioning from single sequencing to integrated solutions in multi-omics, clinical, and data/software [5]. - The acquisition of SomaLogic was announced in June to expand into the proteomics field, further binding customers around sequencing as a core [5]. Updated Financial Guidance - The company raised its full-year revenue guidance from $4.18 billion to $4.26 billion to a new range of $4.23 billion to $4.31 billion [6].